Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    odevixibat | PFIC2
Previous Study | Return to List | Next Study

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2 (PEDFIC 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03566238
Recruitment Status : Completed
First Posted : June 25, 2018
Results First Posted : September 5, 2021
Last Update Posted : September 5, 2021
Information provided by (Responsible Party):

Brief Summary:
Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.

Condition or disease Intervention/treatment Phase
PFIC1 PFIC2 Drug: A4250 (odevixibat) Drug: Placebo Phase 3

Detailed Description:

Up to 50 sites in the following countries will take part in this study:

Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, Turkey, United Kingdom, United States, and Saudi Arabia

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-Blind, Randomized, Placebo-Controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)
Actual Study Start Date : May 16, 2018
Actual Primary Completion Date : July 27, 2020
Actual Study Completion Date : July 28, 2020

Arm Intervention/treatment
Experimental: A4250 low dose
Capsules for oral administration (40 ug/kg) once daily for 24 weeks
Drug: A4250 (odevixibat)
A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).

Experimental: A4250 high dose
Capsules for oral administration (120 ug/kg) once daily for 24 weeks
Drug: A4250 (odevixibat)
A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).

Placebo Comparator: Placebo
Capsules for oral administration (to match active) once daily for 24 weeks
Drug: Placebo
Placebo identical in appearance to active drug (A4250).

Primary Outcome Measures :
  1. Proportion of Positive Pruritus Assessments at the Participant Level Over the 24-week Treatment Period Based on the Albireo Observer-reported Outcome (ObsRO) Instrument (United States Primary Endpoint) [ Time Frame: Over 24 weeks of treatment ]
    ObsRO instrument was used to assess severity of observed scratching twice a day (AM and PM) with score from 0 to 4 where 0 is no scratching and 4 is worst possible scratching. A positive pruritus assessment was defined as a scratching score of <= 1 or at least one point drop from baseline. At each post baseline assessment over the 24-week treatment period, the AM score was compared to the baseline AM average and the PM score was compared to the baseline PM average. Both AM and PM pruritus assessments were included in the analysis. Any intermittently missing assessment or missing planned assessment after premature treatment discontinuation, death, or initiation of rescue treatment was classified as negative assessment. Proportion of positive pruritus assessments at the participant level over the 24-week was then calculated. Full analysis set was used for the analysis.

  2. Percentage of Participants Experiencing at Least a 70% Reduction in Fasting s-BA Concentration From Baseline to the End of Treatment or Reaching a Level <= 70 μmol/L After 24 Weeks of Treatment (European Union and Rest of the World Primary Endpoint) [ Time Frame: Over 24 weeks of treatment ]
    Fasting s-BA baseline was calculated as the average of the last 2 values prior to the first dose. The end value was the average of the values at Weeks 22 and 24 after the start of double-blind treatment. Participants who had at least 70% reduction in Fasting s-BA from baseline to the end of treatment or reached <=70 μmol/L after 24 weeks of treatment were considered as responder. Participants with missing average at the end of treatment were classified as non-responder. Full analysis set was used for the analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • A male or female participant with a clinical diagnosis of PFIC Type 1 or 2 and with a body weight above 5 kg
  • Participant must have clinical genetic confirmation of PFIC-1 or PFIC-2
  • Participant must have elevated serum bile acid (s-BA) concentration
  • Participant must have history of significant pruritus and a caregiver reported observed scratching in the eDiary
  • Participant and/or legal guardian must sign informed consent (and assent) as appropriate.
  • Participants will be expected to have a consistent caregiver(s) for the duration of the study
  • Caregivers and age-appropriate participants (≥8 years of age) must be willing and able to use an eDiary device as required by the study

Key Exclusion Criteria:

  • Participant with pathologic variations of the ABCB11 gene that predict complete absence of the bile salt export pump (BSEP) protein
  • Participant with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Benign recurrent intrahepatic cholestasis, indicated by any history of normal s BAs
    3. Suspected or proven liver cancer or metastasis to the liver on imaging studies
    4. Histopathology on liver biopsy that is suggestive of alternate non-PFIC related etiology of cholestasis
  • Participant with past medical history or ongoing chronic diarrhea
  • Any participant with suspected or confirmed cancers except for basal cell carcinoma
  • Participant with a past medical history of chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m^2
  • Participant with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to start of Screening Period
  • Participant has had a liver transplant or a liver transplant is planned within 6 months of randomization
  • Decompensated liver disease
  • Participant suffers from uncontrolled, recalcitrant pruritic condition other than PFIC
  • Participant who has been previously treated with an IBAT inhibitor whose pruritus has not responded to treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03566238

Show Show 45 study locations
Sponsors and Collaborators
  Study Documents (Full-Text)

Documents provided by Albireo:
Study Protocol  [PDF] June 24, 2019
Statistical Analysis Plan  [PDF] August 25, 2020

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Albireo Identifier: NCT03566238    
Other Study ID Numbers: A4250-005
First Posted: June 25, 2018    Key Record Dates
Results First Posted: September 5, 2021
Last Update Posted: September 5, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Albireo:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases